Ocular melanoma

Surgical Clinics of North America

Volumn 83, Issue 2, 2003, Pages 253-274

  Char, Devron H ^a,b,c  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Tumori Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; RADON;

A SCAN; ADJUVANT THERAPY; B SCAN; BEAM THERAPY; BRACHYTHERAPY; CHOROID MELANOMA; COMPUTER ASSISTED TOMOGRAPHY; CONJUNCTIVAL MELANOMA; CRYOSURGERY; CRYOTHERAPY; ECHOGRAPHY; ENUCLEATION; EYE MELANOMA; GAMMA KNIFE; HUMAN; HYPERTHERMIC THERAPY; IRIS MELANOMA; LASER COAGULATION; LASER SURGERY; LIVER FUNCTION TEST; MELANOMA; MELANOSIS; METASTASIS; PARTICLE RADIATION; PATHOGENESIS; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THORAX RADIOGRAPHY; UVEA MELANOMA;

CONJUNCTIVAL NEOPLASMS; EYE NEOPLASMS; HUMANS; MELANOMA; UVEAL NEOPLASMS;

EID: 0037399426     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(02)00098-1     Document Type: Review

References (123)

1. Parkin DM, Whelan SL, Ferlay J, et al, editors. Cancer incidence in five continents, vol. VII. Lyon: International Agency for Research on Cancer, Scientific Pub No 143;1997.
2. Char DH. Tumors of the eye and ocular adnexa Toronto (BC): Decker; 2001.
3. Thames Cancer Registry. Cancer in south east England 1992. Thames Cancer Registry Report, 1995.
4. Seregard S, Kock E. Conjunctival malignant melanoma in Sweden 1969-1991. Acta Ophthalmol 1992;70:289-96.
5. Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer 1998;83:1664-78.
6. Gass JD, Glatzer RJ. Acquired pigmentation simulating Peutz-Jeghers syndrome: initial manifestation of diffuse uveal melanocytic proliferation. Br J Ophthalmol 1991;75(11):693-5.
7. Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 2001;21(3):173-87.
8. Holly EA, Aston DA, Char DH, et al. Uveal melanoma in relation to ultraviolet light exposure and host factors. Cancer Res 1990;50(18):5773-7.
9. Lutz JM, Cree IA, Foss AJE. Risk factors for intra-ocular melanoma: what is known about occupational exposure? Br J Ophthalmol 1999;83:1190-3.
10. Ghazvini S, Char DH, Kroll S, et al. Comparative genomic hybridization analysis of archival formalin-fixed paraffin-embedded uveal melanomas. Cancer Genet Cytogenet Sep 1996;90(2):95-101.
11. Gordon KB, Thompson CT, Char DH, et al. Comparative genomic hybridization in the detection of DNA copy number abnormalities in uveal melanoma. Cancer Res 1994;54(17):4764-8.
12. Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monostomy 3 in uveal melanoma. Lancet 1996;347:122-25.
13. Sisley K, Cottan DW, Rennie IG, et al. Non-random abnormalities of chromosomes 3, 6 and 8 associated with posterior uveal melanoma. Genes Chromosomes Cancer 1992; 5:197-200.
14. Singh AD, Shields CL, De Potter P, et al. Familial uveal melanoma. Clinical observations on 56 patients. Arch Ophthalmol Apr 1996;114(4):392-9.
15. Char DH. Metastatic choroidal melanoma. Am J Ophthalmol 1978;86:76-80.
16. Folberg R, McLean IW, Zimmerman LE. Malignant melanoma of the conjunctiva. Hum Pathol 1985;16:136-43.
17. Silvers DN, Jakobiec FA, Freeman TR, et al. Melanoma of the conjunctiva: clinical pathologic study. In: Jakobiec FA, editor. Ocular and adnexal tumors. Birmingham (AL): Aesculapius; 1978. p. 585-599.
18. Jay V, Ho M, Hunter W, et al. Expression of p53 in conjunctival melanocytic nevi. An immunohistochemical study. Arch Pathol Lab Med 1996;120:378-9.
19. Reese AB. Precancerous and cancerous melanosis of conjunctiva. Am J Ophthalmol 1955;39:96-100.
20. Folberg R. McLean IW, Zimmerman LE. Primary acquired melanosis of the conjunctiva. Hum Pathol 1985;16:129-35.
21. Grossniklaus HE, Margo CE, Solomon AR. Indeterminate melanocytic proliferations of the conjunctiva. Trans Am Ophthalmol Soc 1999;97:157-70.
22. Demirci H, McCormick SA, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. Arch Ophthalmol 2000;118(7):885-91.
23. Kemp EG, Harnett AN, Chatterjee S. Preoperative topical and intraoperative local mitomyin C adjuvant therapy in the management of ocular surface neoplasias. Br J Ophthalmol 2002;86(1):31-4.
24. Esmaeli B, Eicher S, Popp J, et al. Sentinel lymph node biopsy for conjunctival melanoma. Ophthal Plast Reconstr Surg 2001;17:436-42.
25. Wilson MW, Fleming JC, Fleming RM, et al. Sentinel node biopsy for orbital and ocular adnexal tumors. Ophthal Plast Reconstr Surg 2001;17(5):338-44 [discussion 344-5].
26. Stannard CE, Rossall HS, Egbert RH, et al. Malignant melanoma of the eyelid and palpebral conjunctiva treated with iodine-125 brachytherapy. Ophthalmology 2000; 107:951-8.
27. Anastassiou G, Heiligenhaus A, Bechrakis N, et al. Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J Ophthalmol 2002;86:163-7.
28. Paridaens AD, Minassian DC, McCartney AC, et al. Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathologic study of 256 cases. Br J Ophthalmol 1994;78:252-9.
29. Shields CL, Jagunduz K, Cater J, et al. Conjunctival melanoma. Arch Ophthalmol 2000;118:1497-507.
30. Shields JA, Shields CL, Gunduz K, et al. Clinical features predictive of orbital exenteration for the conjunctival melanoma. Ophthal Plast Reconstr Surg 2000;16: 173-8.
31. Travis LW, Rice DH, McClatchey KD, et al. Malignant melanoma of the conjunctiva metastatic to parotid gland. Report of cases and discussion of surgical management. Laryngoscope 1977;87:2000-7.
32. Kirkwood JM. Systematic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies. Eur J Cancer 1998;34:S12-7.
33. Silcock AQ. Hereditary sarcoma of the eyeball. Trans Pathol Soc Lond 1892;43:140-1.
34. Brantley MA, Harbour JW. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol 2000;157:1795-801.
35. Merbs SL, Sidransky D. Analysis of p16 (CDKN2/MTS/INK4A) alterations in primary sporadic uveal melanoma. Invest Ophthalmol Vis Sci 1999;40:779-83.
36. Aalto Y, Eriksson L, Seregard S, et al. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1,6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci 2001;42:313-7.
37. Naus NC, van Drunen E, deKlein A, et al. Characterization of complex chromosomal abnormalities in uveal melanoma by fluorescence in situ hybridization, spectral karyotyping and comparative genomic hybridization. Genes Chromosomes Cancer 2001;30:267-73.
38. Speicher MR, Prescher G, duManoir S, et al. Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization. Cancer Res 1994; 54:3817-23.
39. Tschentscher F, Prescher G, Zeschnigk M, et al. Identification of chromosomes 3,6 and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. Cancer Genet Cytogenet 2000;122:13-7.
40. Parrella P, Caballero OL, Sidransky D, et al. Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization. Invest Ophthalmol Vis Sci 2001;42: 1679-1684.
41. Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Genet Cancer 1997;19:22-8.
42. Tschentscher F, Prescher G, Horsman DE, et al. Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma. Cancer Res 2001;61:3439-42.
43. White VA, Chambers JD, Courtright PD, et al. Correlation of cytogenetic abnormalities with outcome of patients with melanoma. Cancer 1998;83:354-9.
44. Patel KA, Edmondson ND, Talbot F, et al. Prediction and prognosis in patients with uveal melanoma using fluorescence in situ hybridization. Br J Ophthalmol 2001;85:1440-4.
45. Easton DF, Steele L, Fields P, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 12q12-13. Am J Hun Genet 1997;61:120-8.
46. Houlston RS, Damaor BE. Genetic predisposition to ocular melanoma. Eye 1999;13:704-5.
47. Sinilnikova OM, Egan KM, Quinn JL, et al. Germline brca2 sequence variants in patients with ocular melanoma. Int J Cancer 1999;82:325-8.
48. Van der Velden PA, Metzelaar-Blok JAW, Bergman W, et al. Promoter hypermethylation: a common cause of reduced p16ink4a expression in uveal melanoma. Cancer Res 2001;61:5303-6.
49. Paggi MG, Giordano A. Who is the boss in the retinoblastoma family? The point of view of Rb2/p130, the little brother. Cancer Res 2001;61:4651-4.
50. Mouriaux F, Maurage C-A, Labalette P, et al. Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors. Invest Ophthalmol Vis Sci 2000;41:2837-43.
51. Myatt N, Aristodemou P, Neale MH, et al. Abnormalities of the transforming growth factor-beta pathway in ocular melanoma. J Pathol 2000;192:511-18.
52. Chana JS, Wilson GD, Cree IA, et al. C-myc, p53 and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol 1999;83:110-14.
53. Kishore K, Ghazvini S, Char DH, et al. P53 gene and cell cycling in uveal melanoma. Am J Ophthalmol 1996;121:561-7.
54. Coupland SE, Anastassiou G, Stang A, et al. The prognostic value of cyclin D1, p53 and MDM2 protein expression in uveal melanoma. J Pathol 2000;191:120-6.
55. Ijland SA, Jager MJ, Heijdra BM, et al. Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res 1999;9:445-50.
56. Boyd SR, Tan D, Bunce D, Gittos, et al. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol 2002;86:448-52.
57. Boyd SR, Tan DSW, de Souza L, et al. Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. Br J Ophthalmol 2002;86:440-7.
58. Sheidow TG, Hooper PL, Cruckley C, et al. Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastases. Br J Ophthalmol 2000;84:750-6.
59. Folberg R, Mehaffey M, Gardner LM, et al. The microcirculation of choroidal and ciliary body melanomas. Eye 1997;11(Pt 2):227-38.
60. Hess AR, Seftor EA, Gardner LMG, et al. Molecular regulation of tumor vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001;61:3250-5.
61. Seftor REB, Seftor EA, Koshikawa N, et al. Cooperative interactions of Laminin 5 gamma 2 chain, matrix, metalloproteinase-2, and membrane type-1 matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001;61:6322-27.
62. Elshaw SR, Sisley K, Cross N, et al. A comparison of ocular melanocyte and uveal melanoma invasion and the implications of alpha 1 beta 1, and alpha 4 beta 1, and alpha 6 beta 1 integrins. Br J Ophthalmol 2001;85:732-8.
63. El-Shabrawi Y, Ardjomand N, Radner H, et al. MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma. J Pathol 2001;194:201-6.
64. Larouche N, Larouche K, Beliveau A, et al. Transcriptional regulation of alpha 4 integrin subunit gene in the metastatic spread of uveal melanoma. Anticancer Res 1998;18: 3539-48.
65. Vaisanen A, Kallioinen M, von Dickhoff K, et al. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein - a new prognostic marker in uveal melanoma? J Pathol 1999;188:56-62.
66. Vajdic CM, Kricker A, Giblin M, et al. Eye color and cutaneous nevi predict risk of ocular melanoma in Australia. Int J Cancer 2001;92:906-12.
67. Singh AD, Singh CL, Shields JA, et al. Uveal melanoma in young patients. Arch Ophthalmol 2000;118:918-23.
68. Char DH, Crawford JB, Kroll S. Iris melanomas. Diagnostic problems. Ophthalmology 1996;103:251-5.
69. Jakobiec FA, Silbert G. Are most iris "melanomas" really nevi? A clinicopathologic study of 189 lesions. Arch Ophthalmol 1981;99:2117-32.
70. Shields CL, Shields JA, Materin M, et al. Iris melanomas: risk factors for metastasis in 169 consecutive patients. Ophthalmology 2001;108:172-8.
71. Ganley JP, Comstock GW. Benign nevi and malignant melanomas of the choroid. Am J Ophthalmol 1973;76:19-25.
72. Butler P, Char DH, Zarbin M, et al. Natural history of indeterminate pigmented choroidal tumors. Ophthalmology 1994;101(4):710-6.
73. Char DH, Hogan MJ. Management of small elevated pigmented choroidal lesions. Br J Ophthalmol 1977;61(1):54-8.
74. Desjardins L, Lumbroso L, Levy C, et al. Facteurs de risque pour la degenerescence des naevi choroidiens: etude retrospective sur 135 cas. J Fr Ophtalmol 2001;24:610-16.
75. Shields CL, Cater J, Shields JA, et al. Combination of clinical factors predictive of growth of small choroidal melanocytic tumors. Arch Ophthalmol 2000;118(3):360-4.
76. Char DH, Miller T. Accuracy of presumed uveal melanoma diagnosis before alternative therapy. Br J Ophthalmol 1995;79(7):692-6.
77. Char DH, Stone RD, Irvine AR, et al. Diagnostic modalities in choroidal melanoma. Am J Ophthalmol 1980;89(2):223-30.
78. Char DH, Kroll SM, Miller T, et al. Irradiated uveal melanomas: cytopathologic correlation with prognosis. Am J Ophthalmol 1996;122:509-13.
79. 123I)-iodoamphetamine single photon emission computed tomography for the diagnosis of uveal malignant melanoma. Am J Ophthalmol 2001;132:937-9.
80. Regan S, Egan KM, Hart L, et al. Color doppler imaging of untreated and irradiated new choroidal melanomas. Eur J Ophthalmol 2001;11:150-5.
81. Spraul CW, Lang GE. Value of positron emissions tomography in the diagnosis of malignant ocular tumors. Ophthalmologica 2001;215:163-8.
82. Margo CE. The accuracy of diagnosis of posterior uveal melanoma. Arch Ophthalmol 1997;115(3):432-4.
83. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS report no. 1. Arch Ophthalmol 1990;108(12):1708.
84. Robertson DM, Buettner H, Bennett SR. Transpupillary thermotherapy as primary treatment for small choroidal melanomas. Trans Am Ophthalmol Soc 1999;97:407-34.
85. Shields CL, Shields JA, Perez N, et al. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations. Ophthalmology 2002;109(2):225-34.
86. Stoffelns BM. Primary transpupillary thermotherapy (TTT) for malignant choroidal melanoma. Acta Ophthalmol Scand 2002;80(1):25-31.
87. Augsburger JJ, Correa ZM, Freire J, et al. Long-term survival of choroidal and ciliary body melanoma after enucleation versus plaque radiation therapy. Ophthalmology 1998;105:1607-8.
88. Seddon JM, Gragoudas ES, Egan KM, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology 1990;97:769-77.
89. Seregard S. Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A meta-analysis of studies including 1,066 patients. Acta Ophthalmol Scand 1999; 77:414-7.
90. Diener-West M, Earle JD, Fine SL, et al. The Collaborative Ocular Melanoma Study Group the COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Comment in: Arch Ophthalmol 2001;119(7):1067-8.
91. Harbour JW, Char DH, Kroll S, et al. Metastatic risk for distinct patterns of postirradiation local recurrence of posterior uveal melanoma. Ophthalmology 1997;104:1785-93.
92. Karlsson UL, Augsburger JJ, Shields JA, et al. Recurrence of posterior uveal melanoma after 60 Co episcleral plaque therapy. Ophthalmology 1989;96:382-8.
93. Vrabec TR, Augsburger JJ, Gamel JW, et al. Impact of local tumor relapse on patient survival after cobalt 60 plaque radiotherapy. Ophthalmology 1991;98:984-8.
94. Char DH, Kroll SM, Castro J. Ten-year follow-up of helium ion therapy for uveal melanoma. Am J Ophthalmol 1998;125:81-9.
95. Char DH, Quivey JM, Castro JR, et al. Helium ions versus iodine-125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology 1993;100:1547-54.
96. Egger E, Schalenbourg A, Zografos L, et al. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys 2001;51:138-47.
97. Gragoudas ES. 1996 Jules Gonin lecture of the Retina Research Foundation. Long-term results after proton irradiation of uveal melanomas. Graefes Arch Clin Exp Ophthalmol 1997;235(5):265-7.
98. Meecham WJ, Char DH, Kroll S, et al. Anterior segment complications after helium ion radiation therapy for uveal melanoma. Radiation cataract. Arch Ophthalmol 1994; 112(2):197-203.
99. Daftari IK, Char DH, Verhey LJ, et al. Anterior segment sparing to reduce charged particle radiotherapy complications in uveal melanoma. Int J Radiat Oncol Biol Phys 1997;39(5):997-1010.
100. Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol 2001;118:1219-28.
101. Char DH, Phillips TL, Quivey JM, et al. Late failures after 1-125 brachytherapy. Ophthalmology, in press.
102. Lommatzsch PK, Werschnik C, Schuster E. Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol 2000;238:129-37.
103. Finger PT, Berson A, Szechter A. Palladium-103 plaque radiotherapy for choroidal melanoma: results of a seven-year study. Ophthalmology 1999;106:606-13.
104. Karvat A, Duzenli C, Ma R, et al. The treatment of choroidal melanoma with 198-Au plaque brachytherapy. Radiotherapy Oncol 2001;59:153-6.
105. Kaulich TW, Zurheide J, Fluhs D, et al. Therapy relevant weak sites in industrial quality assurance of 106Ru eye plaques. Strahleuther Onkol 2001;177:616-23.
106. Quivey JM, Augsburger J, Snelling L, et al. 125-I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control. Cancer 1996;77(11):2356-62.
107. Dieckmann K, Bogner J, Georg D, et al. A linac-based stereotactic irradiation technique of uveal melanoma. Radiother Oncol 2001;61(1):49-56.
108. Langmann G, Pendl G, Klaus-Mullner L, et al. Gamma knife radiosurgery for uveal melanomas: an 8-year experience. J Neurosurg Dec 2000;93(Suppl 3):184-8.
109. Mueller AJ, Tallies S, Schaller UC, et al. Stereotactic radiosurgery of large uveal melanomas with the gamma-knife. Ophthalmology 2000;107:1381-8.
110. Zehetmayer M, Kitz K, Menapace R, et al. Local tumor control and morbidity after one to three fractions of stereotactic external beam irradiation for uveal melanoma. Radiother Oncol 2000;55(2):135-44.
111. Matsumura Y, Yamagishi N, Miyakoshi J, et al. Increase in radiation sensitivity of human malignant melanoma cells by expression of wild-type p16 gene. Cancer Lett 1997;115:91-6.
112. Brantley MA Jr, Worley L, Harbour JW. Altered expression of Rb and p53 in uveal melanomas following plaque radiotherapy. Am J Ophthalmol 2002;133:242-8.
113. Char DH, Miller T, Crawford JB. Uveal tumour resection. Br J Ophthalmol 2001;85(10):1213-9.
114. Bechrakis NE, Bornfeld N, Zoller I, et al. Jod-125 Brachytherapie und transsklerale Tumor-resektion bei grossen uvealen Melanomen. Ophthalmologie 2001;98:736-42.
115. Char DH, Phillips TL, Andejeski Y, et al. Failure of pre-enucleation radiation decreasing uveal melanoma mortality. Am J Ophthalmol 1988;106:21-6.
116. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre enucleation radiation of large choroidal melanoma: initial mortality findings. COMS report no. 10. Am J Ophthalmol 1998;125(6):865-7.
117. Eskelin S, Pyrhonen S, Summanen P, et al. Screening for metastatic malignant melanoma of the uvea revisited. Cancer 1999;85(5):1151-9.
118. Hicks C, Foss AJ, Hungerford JL. Predictive power of screening tests for metastasis in uveal melanoma. Eye 1998;12(Pt 6):945-8.
119. Reske SN, Kotzerke J. FDG-PET for clinical use. Eur J Nucl Med 2001;28:1707-23.
120. Char DH, Schwartz A, Miller TR, et al. Ocular metastases from systemic melanoma. Am J Ophthalmol 1980;90(5):702-7.
121. Orcutt JC, Char DH. Melanoma metastatic to the orbit. Ophthalmology 1988;95(8):1033-7.
122. Borkowski LM, Grover S, Fishman GA, et al. Retinal findings in melanoma-associated retinopathy. Am J Ophthalmol 2001;132:273-5.
123. Zacks DN, Pinnolis MK, Berson EL, et al. Melanoma-associated retinopathy and recurrent exudative retinal detachments in a patient with choroidal melanoma. Am J Ophthalmol 2001;132:578-81.